Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2016 Aug;18(8):652-63.
doi: 10.1016/j.hpb.2016.05.004. Epub 2016 Jul 14.

Systematic review of peri-operative prognostic biomarkers in pancreatic ductal adenocarcinoma

Wilson Petrushnko  1 , Justin S Gundara  1 , Philip R De Reuver  1 , Greg O'Grady  2 , Jaswinder S Samra  1 , Anubhav Mittal  3
Affiliations

Systematic review of peri-operative prognostic biomarkers in pancreatic ductal adenocarcinoma

Wilson Petrushnko et al. HPB (Oxford). 2016 Aug.

Abstract

Background: Pancreatic ductal adenocarcinoma (PDAC) continues to be associated with a poor prognosis. This systematic review aimed to summarize the literature regarding potential prognostic biomarkers to facilitate validation studies and clinical application.

Methods: A systematic review was performed (2004-2014) according to PRISMA guidelines. Studies were ranked using REMARK criteria and the following outcomes were examined: overall/disease free survival, nodal involvement, tumour characteristics, metastasis, recurrence and resectability.

Results: 256 biomarkers were identified in 158 studies. 171 biomarkers were assessed with respect to overall survival: urokinase-type plasminogen activator receptor, atypical protein kinase C and HSP27 ranked the highest. 33 biomarkers were assessed for disease free survival: CD24 and S100A4 were the highest ranking. 17 biomarkers were identified for lymph node involvement: Smad4/Dpc4 and FOXC1 ranked highest. 13 biomarkers were examined for tumour grade: mesothelin and EGFR were the highest ranking biomarkers. 10 biomarkers were identified for metastasis: p16 and sCD40L were the highest ranking. 4 biomarkers were assessed resectability: sCD40L, s100a2, Ca 19-9, CEA.

Conclusion: This review has identified and ranked specific biomarkers that should be a primary focus of ongoing validation and clinical translational work in PDAC.

PubMed Disclaimer

Figures

Figure 1
Figure 1
PRISMA flowchart: publications included and excluded
Figure 2
Figure 2
Detection methodology
Figure 3
Figure 3
Biomarker category
Figure 4
Figure 4
Biomarker functional groups
See this image and copyright information in PMC

Comment in

References

    1. Ying J.-E., Zhu L.-M., Liu B.-X. Developments in metastatic pancreatic cancer: is gemcitabine still the standard? World J Gastroenterol. 2012 Feb 28;18:736–745. http://paperpile.com/b/dbz9iT/XPvhr - PMC - PubMed
    1. Halloran C.M., Ghaneh P., Connor S., Sutton R., Neoptolemos J.P., Raraty M.G.T. Carbohydrate antigen 19.9 accurately selects patients for laparoscopic assessment to determine resectability of pancreatic malignancy. Br J Surg. 2008 Apr;95:453–459. http://paperpile.com/b/dbz9iT/NYiG2 - PubMed
    1. Michalski Christoph W., Erkan Mert, Hüser Norbert, Müller Michael W., Hartel Mark, Friess Helmut. Resection of primary pancreatic cancer and liver metastasis: a systematic review. Dig Surg. 2008;25:473–480. http://paperpile.com/b/dbz9iT/R8huE - PubMed
    1. Lopez N.E., Prendergast C., Lowy A.M. Borderline resectable pancreatic cancer: definitions and management. World J Gastroenterol. 2014 Aug 21;20:10740–10751. http://paperpile.com/b/dbz9iT/CTrAe - PMC - PubMed
    1. Katz M.H.G., Marsh R., Herman J.M., Shi Q., Collison E., Venook A.P. Borderline resectable pancreatic cancer: need for standardization and methods for optimal clinical trial design. Ann Surg Oncol. 2013 Aug;20:2787–2795. http://paperpile.com/b/dbz9iT/t8aeP - PMC - PubMed

Further reading

    1. Roselli M., Mineo T.C., Basili S., Mariotti S., Martini F., Bellotti A. Vascular endothelial growth factor (VEGF-A) plasma levels in non-small cell lung cancer: relationship with coagulation and platelet activation markers. Thromb Haemost. 2003 Jan;89:177–184. http://paperpile.com/b/dbz9iT/hAmy5 - PubMed
    1. Abramson M.A., Jazag A., van der Zee J.A., Whang E.E. The molecular biology of pancreatic cancer. Gastrointest Cancer Res. 2007;1:S7–S12. http://paperpile.com/b/dbz9iT/e9JEm - PMC - PubMed
    1. Nagata S., Jin Y.-F., Yoshizato K., Tomoeda M., Song M., Iizuka N. CD74 is a novel prognostic factor for patients with pancreatic cancer receiving multimodal therapy. Ann Surg Oncol. 2009 Sep;16:2531–2538. http://paperpile.com/b/dbz9iT/DgHdb - PubMed
    1. Miyoshi K., Sato N., Ohuchida K., Mizumoto K., Tanaka M. SPARC mRNA expression as a prognostic marker for pancreatic adenocarcinoma patients. Anticancer Res. 2010 Mar;30:867–871. http://paperpile.com/b/dbz9iT/GnQn4 - PubMed
    1. Park J.K., Kim M.A., Ryu J.K., Yoon Y.B., Kim S.-W., Han H.-S. Postoperative prognostic predictors of pancreatic ductal adenocarcinoma: clinical analysis and immunoprofile on tissue microarrays. Ann Surg Oncol. 2012 Aug;19:2664–2672. http://paperpile.com/b/dbz9iT/8TWvO - PubMed

Publication types

MeSH terms

Substances